Page last updated: 2024-10-28

haloperidol and Motor Neuron Disease

haloperidol has been researched along with Motor Neuron Disease in 2 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Motor Neuron Disease: Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)

Research Excerpts

ExcerptRelevanceReference
" VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)."1.38The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012)
"Frontotemporal lobar degeneration (FTLD) is the most common cause of early-onset dementia."1.36Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. ( Barcikowska, M; Blair, IP; Brooks, WS; Coupland, KG; Dobson-Stone, C; Halliday, GM; Karlström, H; Kwok, JB; Loy, CT; Luty, AA; Maruszak, A; Mather, KA; Panegyres, PK; Sachdev, PS; Schofield, PR; Sobow, T; Tchorzewska, J; Williams, KL; Zekanowski, C, 2010)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Luty, AA1
Kwok, JB1
Dobson-Stone, C1
Loy, CT1
Coupland, KG1
Karlström, H1
Sobow, T1
Tchorzewska, J1
Maruszak, A1
Barcikowska, M1
Panegyres, PK1
Zekanowski, C1
Brooks, WS1
Williams, KL1
Blair, IP1
Mather, KA1
Sachdev, PS1
Halliday, GM1
Schofield, PR1
Jones, CK1
Bubser, M1
Thompson, AD1
Dickerson, JW1
Turle-Lorenzo, N1
Amalric, M1
Blobaum, AL1
Bridges, TM1
Morrison, RD1
Jadhav, S1
Engers, DW1
Italiano, K1
Bode, J1
Daniels, JS1
Lindsley, CW1
Hopkins, CR1
Conn, PJ1
Niswender, CM1

Other Studies

2 other studies available for haloperidol and Motor Neuron Disease

ArticleYear
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease.
    Annals of neurology, 2010, Volume: 68, Issue:5

    Topics: Aged; Aged, 80 and over; Brain; Cell Line, Transformed; DNA-Binding Proteins; Female; Frontotemporal

2010
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 340, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling

2012